MICROBIO-LMC = Interaction Between Gut Microbiota and TKIs in Patients With CML [Italy]
Study title
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML (MICROBIO-LMC)
Scientific title
Interaction Between Gut Microbiota and Tyrosine Kinase Inhibitors in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia
Type of study
Observational study
Phase
Current status
Recruiting
What is the purpose of the study
This is an observational study to assess the effects of gut microbiota, a collection of microorganisms in a person’s gastrointestinal system, on outcomes of treatment with tyrosine kinase inhibitors (TKIs) in patients with Chronic Myeloid Leukemia.
Key inclusion criteria
This study includes patients of all sexes who:
- are aged 18 years and older.
- have Chronic Myeloid Leukemia (CML) at any stage of the disease.
Further criteria may apply. Please discuss these with your doctor or study staff.
Key exclusion criteria
None
Estimated primary completion date
Where can I find additional information
You can find a study description in the US register ClinicalTrials.gov, This is a database provided by the U. S. National Institutes of Health.
Study sponsor
Carmen Fava, University of Turin, in collaboration with Pfizer and Novartis
Scientific lead / contact
Carmen Fava, University of Turin
Principal investigator
Carmen Fava, Department of Clinical and Biological Sciences, University of Turin, Italy
Study centers / principal investigators
Italy
AO Ordine Mauriziano di Torino
Department of Clinical and Biological Sciences
Torino, 10128